HRP20211478T1 - Imunoterapijski režimi doziranja koji obuhvaćaju pomalidomid i anti-cs1 antitijelo za liječenje raka - Google Patents
Imunoterapijski režimi doziranja koji obuhvaćaju pomalidomid i anti-cs1 antitijelo za liječenje raka Download PDFInfo
- Publication number
- HRP20211478T1 HRP20211478T1 HRP20211478TT HRP20211478T HRP20211478T1 HR P20211478 T1 HRP20211478 T1 HR P20211478T1 HR P20211478T T HRP20211478T T HR P20211478TT HR P20211478 T HRP20211478 T HR P20211478T HR P20211478 T1 HRP20211478 T1 HR P20211478T1
- Authority
- HR
- Croatia
- Prior art keywords
- dose
- administered
- days
- elotuzumab
- orally
- Prior art date
Links
- 229960000688 pomalidomide Drugs 0.000 title claims 10
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 title claims 10
- 206010028980 Neoplasm Diseases 0.000 title claims 4
- 201000011510 cancer Diseases 0.000 title claims 2
- 230000001024 immunotherapeutic effect Effects 0.000 title 1
- 229960004137 elotuzumab Drugs 0.000 claims 17
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 9
- 229960003957 dexamethasone Drugs 0.000 claims 9
- 238000011285 therapeutic regimen Methods 0.000 claims 7
- 208000034578 Multiple myelomas Diseases 0.000 claims 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 6
- 230000003442 weekly effect Effects 0.000 claims 5
- 238000002648 combination therapy Methods 0.000 claims 4
- 229960004942 lenalidomide Drugs 0.000 claims 3
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 238000011221 initial treatment Methods 0.000 claims 2
- 101710085938 Matrix protein Proteins 0.000 claims 1
- 101710127721 Membrane protein Proteins 0.000 claims 1
- 102100032965 Myomesin-2 Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000004180 plasmocyte Anatomy 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 230000005748 tumor development Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Claims (11)
1. Kombinirani terapijski režim u kome se svaka komponenta navedene kombinacije zasebno administrira, koji obuhvaća: (i) terapijski efikasnu količinu pomalidomida; (ii) terapijski efikasnu količinu elotuzumaba, i (iii) terapijski prihvatljivu količinu deksametazona, za primjenu u postupku liječenja pacijenta sa multiplim mijelomom koji je napredovao nakon primanja inicijalnog tretmana, pri čemu navedena kombinacija zaustavlja navedenu progresiju i efikasno liječi multipli mijelom navedenog pacijenta.
2. Kombinirani terapijski režim za primjenu iz patentnog zahtjeva 1, pri čemu je početno liječenje liječenje lenalidomidom.
3. Kombinirani terapijski režim u kome se svaka komponenta navedene kombinacije zasebno administrira, koji obuhvaća: (i) terapijski efikasnu količinu pomalidomida; (ii) terapijski efikasnu količinu elotuzumaba, i (iii) terapijski prihvatljivu količinu deksametazona, za primjenu u postupku liječenja pacijenta sa multiplim mijelomom koji je rezistentan na lenalidomid, pri čemu navedena kombinacija nadilazi rezistentnost navedenog pacijenta na lenalidomid i efikasno liječi multipli mijelom navedenog pacijenta.
4. Kombinirani terapijski režim za primjenu prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu se pomalidomid administrira u dozi od 4 mg, elotuzumab se administrira u dozi od 10 mg/kg, i deksametazon se administrira bilo oralno u dozi od 28 mg do 40 mg, ili putem IV u dozi od 8 mg.
5. Kombinirani terapijski režim za primjenu prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu se pomalidomid administrira u dozi od 4 mg na dan tokom 21 dana, elotuzumab se administrira u dozi od 10 mg/kg tjedno, i deksametazon se administrira bilo oralno u dozi od 28 mg do 40 mg na dan tokom 21 dana, ili putem IV u dozi od 8 mg tjedno.
6. Kombinirani terapijski režim za primjenu prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu
(i) pomalidomid se administrira u dozi od 4 mg oralno 1-21. dana svakog ciklusa,
(ii) elotuzumab se administrira u dozi od 10 mg/kg intravenski (IV) 1, 8, 15. i 22. dana ciklusa 1 i 2, a potom se administrira u dozi od 20 mg/kg IV 1. dana ciklusa 3 i nakon, i
(iii) deksametazon se administrira u dozi od 28 mg oralno i 8 mg IV na dane doziranja elotuzumaba (1, 8,15. i 22. dan ciklusa 1 i 2 i 1. dan ciklusa 3 i nakon), i u dozi od 40 mg oralno po tjednu, tjedno bez doziranja elotuzumaba kod subjekata ≤ 75 godina starosti, i
administrira u dozi od 8 mg oralno i 8 mg IV na dane kad se dozira elotuzumab (1, 8, 15. i 22. dan ciklusa 1 i 2 i 1. dana ciklusa 3 i nakon), i u dozi od 20 mg oralno po tjednu, tjednom bez doziranja elotuzumaba kod subjekata > 75 godina starosti,
pri čemu se ciklus definira kao 28 dana.
7. Kombinirani terapijski režim u kome se svaka komponenta navedene kombinacije zasebno administrira, koji obuhvaća: (i) terapijski efikasnu količinu pomalidomida; (ii) terapijski efikasnu količinu elotuzumaba, i (iii) terapijski prihvatljivu količinu deksametazona, za primjenu u metodi za liječenje pacijenta sa multiplim mijelomom, pri čemu navedena kombinacija efikasno liječi multipli mijelom navedenog pacijenta.
8. Kombinirani terapijski režim za primjenu iz patentnog zahtjeva 7, pri čemu se pomalidomid administrira u dozi od 4 mg, elotuzumab se administrira u dozi od 10 mg/kg, i deksametazon se administrira bilo oralno u dozi od 28 mg do 40 mg, ili putem IV u dozi od 8 mg.
9. Kombinirani terapijski režim za primjenu iz patentnog zahtjeva 7, pri čemu se pomalidomid administrira u dozi od 4 mg na dan tokom 21 dana, elotuzumab se administrira u dozi od 10 mg/kg tjedno, i deksametazon se administrira bilo oralno u dozi od 28 mg do 40 mg na dan tokom 21 dana, ili putem IV u dozi od 8 mg tjedno u ukupnom ciklusu doziranja od 28 dana, i po izboru gdje se elotuzumab administrira u dozi od 20 mg/kg u naknadnim ciklusima doziranja koji nisu prvi i drugi ciklus.
10. Kombinirani terapijski režim za primjenu iz patentnog zahtjeva 7, pri čemu
(i) pomalidomid se administrira u dozi od 4 mg oralno 1-21. dana svakog ciklusa,
(ii) elotuzumab se administrira u dozi od 10 mg/kg intravenski (IV) 1, 8, 15. i 22. dana ciklusa 1 i 2, a potom administrira u dozi od 20 mg/kg IV 1. dana ciklusa 3 i nakon, i
(iii) deksametazon se administrira u dozi od 28 mg oralno i 8 mg IV danima kad se dozira elotuzumab (1, 8,15. i 22. dan ciklusa 1 i 2 i 1. dan ciklusa 3 i nakon), i u dozi od 40 mg oralno po tjednu, tjedno bez doziranja elotuzumaba kod subjekata ≤ 75 godina starosti, i
administrira se u dozi od 8 mg oralno i 8 mg IV danima kada se dozira (1, 8, 15. i 22. dan ciklusa 1 i 2 i 1. dan ciklusa 3 i nakon), i u dozi od 20 mg oralno po tjednu, tjedno bez doziranja elotuzumaba kod subjekata > 75 godina starosti,
pri čemu se ciklus definira kao 28 dana.
11. Kombinirani terapijski režim za primjenu prema bilo kojem od patentnih zahtjeva 1 do 10, pri čemu navedena kombinacija dovodi do sinergističkog smanjenja opterećenja tumorom, regresije tumora, razvoja tumora, smanjenja nivoa M-proteina, plazma stanica i/ili regresije spomenutog raka.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185968P | 2015-06-29 | 2015-06-29 | |
| US201562239965P | 2015-10-11 | 2015-10-11 | |
| US201562262574P | 2015-12-03 | 2015-12-03 | |
| PCT/US2016/039723 WO2017003990A1 (en) | 2015-06-29 | 2016-06-28 | Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer |
| EP16738609.3A EP3313528B1 (en) | 2015-06-29 | 2016-06-28 | Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211478T1 true HRP20211478T1 (hr) | 2021-12-24 |
Family
ID=56409706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211478TT HRP20211478T1 (hr) | 2015-06-29 | 2016-06-28 | Imunoterapijski režimi doziranja koji obuhvaćaju pomalidomid i anti-cs1 antitijelo za liječenje raka |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10925867B2 (hr) |
| EP (2) | EP3313528B1 (hr) |
| JP (1) | JP6754785B2 (hr) |
| CN (1) | CN107949425A (hr) |
| BR (1) | BR112017027692A2 (hr) |
| CA (1) | CA2990478A1 (hr) |
| CY (1) | CY1124543T1 (hr) |
| DK (1) | DK3313528T3 (hr) |
| EA (1) | EA035888B1 (hr) |
| ES (1) | ES2886657T3 (hr) |
| HR (1) | HRP20211478T1 (hr) |
| HU (1) | HUE056491T2 (hr) |
| LT (1) | LT3313528T (hr) |
| MX (1) | MX2017015765A (hr) |
| PL (1) | PL3313528T3 (hr) |
| PT (1) | PT3313528T (hr) |
| RS (1) | RS62352B1 (hr) |
| SI (1) | SI3313528T1 (hr) |
| WO (1) | WO2017003990A1 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170042598A (ko) * | 2014-08-22 | 2017-04-19 | 셀진 코포레이션 | 항체와 조합된 면역조절 화합물을 이용하여 다발성 골수종을 치료하는 방법 |
| RS62352B1 (sr) * | 2015-06-29 | 2021-10-29 | Bristol Myers Squibb Co | Imunoterapijski režimi doziranja koji obuhvataju pomalidomid i anti-cs1 antitelo za lečenje kancera |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA204125A (en) | 1920-09-21 | Sylvester Pratt Edwin | Gramophone operated toy | |
| US819826A (en) | 1905-12-14 | 1906-05-08 | Frank R Welcher | Stanchion. |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| KR100849443B1 (ko) | 1998-12-23 | 2008-07-31 | 화이자 인크. | Ｃｔｌａ－４에 대한 인간 단일클론 항체 |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| US6262094B1 (en) | 1999-02-22 | 2001-07-17 | Bristol-Myers Squibb Company | C-21 modified epothilones |
| US7629360B2 (en) | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| AU2001233027A1 (en) | 2000-01-27 | 2001-08-07 | Genetics Institute, Llc | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| US7041499B2 (en) | 2001-12-12 | 2006-05-09 | University Of North Texas Health Science Center | Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| CA2476983C (en) * | 2002-05-17 | 2011-01-25 | Celgene Corporation | Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of multiple myeloma |
| KR20100050587A (ko) | 2002-10-17 | 2010-05-13 | 젠맵 에이/에스 | Ｃｄ20에 대한 인간 모노클로날 항체 |
| US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| US6958115B2 (en) | 2003-06-24 | 2005-10-25 | The United States Of America As Represented By The Secretary Of The Navy | Low temperature refining and formation of refractory metals |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| CN101534860B (zh) * | 2006-08-07 | 2013-03-27 | 艾伯特生物治疗学公司 | 使用抗cs1-抗体治疗多发性骨髓瘤的组合物和方法 |
| ES2391790T3 (es) * | 2006-08-07 | 2012-11-29 | Abbott Biotherapeutics Corp. | Composiciones y procedimientos que utilizan los anticuerpos anti-CS1 para tratar el mieloma múltiple |
| ES2589302T3 (es) * | 2006-08-07 | 2016-11-11 | Abbvie Biotherapeutics Inc. | Métodos de tratamiento de mieloma múltiple utilizando terapias de combinación basadas en HuLuc63 con bortezemib |
| WO2008019379A2 (en) | 2006-08-07 | 2008-02-14 | Pdl Biopharma, Inc. | Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells |
| US8603477B2 (en) | 2008-10-31 | 2013-12-10 | Abbvie Biotherapeutics Inc. | Use of anti-CS1 antibodies for treatment of rare lymphomas |
| EP2391355B1 (en) | 2009-05-19 | 2017-01-18 | Celgene Corporation | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
| WO2011053321A1 (en) | 2009-10-30 | 2011-05-05 | University Of Arkansas For Medical Science | Use of autologous effector cells for treatment of multiple myeloma |
| WO2011053322A1 (en) | 2009-10-30 | 2011-05-05 | University Of Arkansas For Medical Science | Use of autologous effector cells and antibodies for treatment of multiple myeloma |
| US9506481B1 (en) | 2013-01-31 | 2016-11-29 | Daniel Theobald | High force hydraulic actuator |
| US20160331698A1 (en) * | 2014-01-13 | 2016-11-17 | University Of Central Florida Research Foundation, Inc. | Fullerene compounds as antioxidant therapy |
| KR20170042598A (ko) | 2014-08-22 | 2017-04-19 | 셀진 코포레이션 | 항체와 조합된 면역조절 화합물을 이용하여 다발성 골수종을 치료하는 방법 |
| EP3212668B1 (en) | 2014-10-31 | 2020-10-14 | AbbVie Biotherapeutics Inc. | Anti-cs1 antibodies and antibody drug conjugates |
| RS62352B1 (sr) * | 2015-06-29 | 2021-10-29 | Bristol Myers Squibb Co | Imunoterapijski režimi doziranja koji obuhvataju pomalidomid i anti-cs1 antitelo za lečenje kancera |
-
2016
- 2016-06-28 RS RS20211157A patent/RS62352B1/sr unknown
- 2016-06-28 EP EP16738609.3A patent/EP3313528B1/en active Active
- 2016-06-28 PT PT167386093T patent/PT3313528T/pt unknown
- 2016-06-28 WO PCT/US2016/039723 patent/WO2017003990A1/en active Application Filing
- 2016-06-28 LT LTEPPCT/US2016/039723T patent/LT3313528T/lt unknown
- 2016-06-28 CN CN201680049473.8A patent/CN107949425A/zh active Pending
- 2016-06-28 HR HRP20211478TT patent/HRP20211478T1/hr unknown
- 2016-06-28 HU HUE16738609A patent/HUE056491T2/hu unknown
- 2016-06-28 EP EP21187060.5A patent/EP3950065A1/en not_active Withdrawn
- 2016-06-28 PL PL16738609T patent/PL3313528T3/pl unknown
- 2016-06-28 US US15/738,412 patent/US10925867B2/en active Active
- 2016-06-28 ES ES16738609T patent/ES2886657T3/es active Active
- 2016-06-28 JP JP2017568264A patent/JP6754785B2/ja active Active
- 2016-06-28 EA EA201890035A patent/EA035888B1/ru not_active IP Right Cessation
- 2016-06-28 MX MX2017015765A patent/MX2017015765A/es unknown
- 2016-06-28 DK DK16738609.3T patent/DK3313528T3/da active
- 2016-06-28 SI SI201631351T patent/SI3313528T1/sl unknown
- 2016-06-28 BR BR112017027692A patent/BR112017027692A2/pt not_active Application Discontinuation
- 2016-06-28 CA CA2990478A patent/CA2990478A1/en active Pending
-
2021
- 2021-01-15 US US17/150,099 patent/US20210154183A1/en not_active Abandoned
- 2021-09-28 CY CY20211100854T patent/CY1124543T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210154183A1 (en) | 2021-05-27 |
| US10925867B2 (en) | 2021-02-23 |
| WO2017003990A1 (en) | 2017-01-05 |
| SI3313528T1 (sl) | 2021-11-30 |
| CY1124543T1 (el) | 2022-07-22 |
| EP3313528A1 (en) | 2018-05-02 |
| BR112017027692A2 (pt) | 2018-10-09 |
| CA2990478A1 (en) | 2017-01-05 |
| CN107949425A (zh) | 2018-04-20 |
| HUE056491T2 (hu) | 2022-02-28 |
| US20180185348A1 (en) | 2018-07-05 |
| EP3950065A1 (en) | 2022-02-09 |
| MX2017015765A (es) | 2018-04-13 |
| LT3313528T (lt) | 2021-10-11 |
| JP6754785B2 (ja) | 2020-09-16 |
| EP3313528B1 (en) | 2021-08-04 |
| ES2886657T3 (es) | 2021-12-20 |
| RS62352B1 (sr) | 2021-10-29 |
| JP2018522881A (ja) | 2018-08-16 |
| PL3313528T3 (pl) | 2021-12-13 |
| PT3313528T (pt) | 2021-09-16 |
| EA201890035A1 (ru) | 2018-06-29 |
| EA035888B1 (ru) | 2020-08-27 |
| DK3313528T3 (da) | 2021-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ725006A (en) | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns | |
| MX2018011054A (es) | Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3. | |
| JP2016518387A5 (hr) | ||
| SG10201811185YA (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
| JP2016513640A5 (hr) | ||
| RU2019109464A (ru) | Способы применения биспецифического антитела, которое распознает фактор свертывания ix и/или активированный фактор свертывания ix и фактор свертывания x и/или активированный фактор свертывания x | |
| JP2017537927A5 (hr) | ||
| MX2018003028A (es) | Reduccion de los niveles o de la actividad de los linfocitos t reguladores sistemicos para el tratamiento de enfermedades y lesiones del sistema nervioso central (snc). | |
| RU2018103064A (ru) | Комбинация ингибитора hdac и анти-pd-l1-антитела для лечения злокачественной опухоли | |
| MX2009012598A (es) | Formas de dosis que comprenden vx-950 y su regimen de dosificacion. | |
| AR087356A1 (es) | Terapia de combinacion para el tratamiento de sintomas de tumores malignos de celulas b cd19que comprende inmunoconjugado maitansinoide anti-cd19 y rituximab | |
| WO2017042633A3 (en) | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns | |
| EA201891388A1 (ru) | Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека | |
| FI3463457T3 (fi) | Pd-1-esto nivolumabilla refraktaarinen hodgkinin lymfoomassa | |
| HRP20211478T1 (hr) | Imunoterapijski režimi doziranja koji obuhvaćaju pomalidomid i anti-cs1 antitijelo za liječenje raka | |
| MX2018009867A (es) | Metodos que comprenden una dosificacion intermitente fija de cediranib. | |
| MX2022005628A (es) | Regimen de dosificacion para agentes anti-bcma. | |
| JP2018522881A5 (hr) | ||
| MX2019013014A (es) | Tratamiento de carcinoma hepatocelular. | |
| RU2013126798A (ru) | Комбинированная терапия дексаметазоном | |
| Poelen | Thrombocytopenia: case report | |
| Kamimura | Bortezomib/lenalidomide | |
| Mekinian | Infliximab/tocilizumab | |
| AR102494A1 (es) | Métodos para tratar enfermedades oculares | |
| Celen | Peginterferon-α-2a |